Get the app
US › Healthcare

Aardvark Therapeutics, Inc. Common Stock (AARD)

US · Healthcare · Biotechnology

$3.78-2.07%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-14.4M
EPS
$-0.66
EPS estimate
$-0.87

EPS came in at -0.66 against a street estimate of -0.87 — a beat of 24.1%.

Key statistics

Market cap
$82.7M
Forward P/E
0.0
P/B
1.63
Book value
$3.42
EPS (TTM)
$-3.10
52-week high
$16.60
52-week low
$3.35
50-day MA
$5.72
200-day MA
$6.95

Analyst view

Analysts rate Aardvark Therapeutics, Inc. Common Stock a buy (6 buy, 4 hold, 2 sell out of 12) with an average price target of $11.11.

Shareholding

Insiders
15.77%
Institutions
52.61%

Largest institutional holders

FundStake
Decheng Capital LLC17.90%
Citadel Advisors Llc5.86%
LAURION CAPITAL MANAGEMENT LP4.73%
Vanguard Capital Management, LLC2.57%
AQR Capital Management LLC2.19%
EcoR1 Capital, LLC1.81%
Adage Capital Partners Gp LLC1.37%
CANTOR FITZGERALD, L. P.1.07%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Aardvark Therapeutics, Inc. Common Stock — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.